At the news
? BULLISHIMPACT 6/10 8-K filed Nov 2, 2026 at 07:00 ET
The company raised full-year 2026 revenue guidance to $1.60-$1.605B (from $1.595-$1.605B), representing ~25% annual growth, and reiterated ~$65M Adjusted EBITDA. Key operational highlights include 32% oncology volume growth, 33% Data & Apps revenue growth, and major collaborations with BMS ($137.5M) and Merck/Moderna. The Personalis acquisition cleared regulatory review with a shareholder vote scheduled for November 30, 2026.
- Q3 2026 total revenue of $411.5M, up 23% YoY from $334.2M
- GAAP net loss of $(14.9)M vs $(80.0)M in Q3 2025, improvement of 81%
- Adjusted EBITDA of $25.6M vs $1.5M in Q3 2025, a 1,633% increase
- Full-year 2026 revenue guidance raised to $1.60-$1.605B from $1.595-$1.605B
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access